IP Library › Granted Patent US 12,268,774
Granted Patent B2
US 12,268,774 · App. 18/397,091 · Granted Apr 8, 2025

Compositions and methods for in utero delivery

Inventors: W. Mark Saltzman (New Haven, CT); David H. Stitelman (Branford, CT); James Stephen Farrelly (Milford, CT); Anthony Bianchi (Liverpool, NY)
Assignee: YALE UNIVERSITY
A61K9/0034A61K9/0019A61K9/1647A61K9/1652A61K9/5153A61K38/1825A61K47/60A61K48/0041A61P7/00A61P11/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,268,774
App. No.
18/397,091
Granted
Apr 8, 2025
Kind
B2
Abstract

Compositions and methods for fetal or in utero delivery of active agents are provided. The compositions are most typically administered intravenously via the vitelline vein, umbilical vein, or directly into the amniotic cavity of a pregnant mother. Fibroblast growth factor is to correct structural defects of neural tissue.

Claims (17)

1. A method comprising administering by injection into the amniotic fluid of a 15 to 20 week human embryo or fetus having exposed spinal cord or brain tissue, an effective amount of a composition comprising fibroblast growth factor encapsulated, entrapped, complexed to or dispersed in polymeric microparticles having a diameter from about 5 to about 10 microns and a zeta potential between −32.8 and −47 mV to cause epithelial tissue to form over the exposed spinal cord or brain tissue in the embryo or fetus, wherein the microparticles are formed of alginate, poly(lactic acid)(PLA), poly(glycolic acid)(PGA), poly(lactide-co-glycolide)(PLGA), polyanhydrides, poly(ortho) esters, poly(caprolactone), poly(hydroxyalkanoates), poly(lactide-co-caprolactone), poly(beta-amino) esters (PBAEs) or poly(amine-co-ester) polymers(PACE).

2. The method of claim 1 , wherein the microparticles are formed of poly(lactic acid)(PLA), poly(glycolic acid)(PGA), poly(lactide-co-glycolide)(PLGA), polyanhydrides, poly(ortho)esters, poly(caprolactone), poly(hydroxyalkanoates), poly(lactide-co-caprolactone), poly(beta-amino)esters(PBAEs) or poly(amine-co-ester)polymers (PACE).

3. The method of claim 2 , wherein the microparticles are formed of polylactide-co-glycolide (PLGA).

4. The method of claim 1 , wherein the microparticles are formed of alginate encapsulating the fibroblast growth factor.

5. The method of claim 1 wherein the composition is administered into the amniotic fluid of the embryo or fetus having exposed spinal cord.

6. The method of claim 1 wherein the composition is injected using an ultrasonic guided needle inserted into the amniotic sac.

7. The method of claim 1 wherein the fetus or embryo is human and is about 14, 15, 16, or 17 weeks of age.

8. The method of claim 1 wherein the microparticles release an amount of fibroblast growth factor to produce picogram levels of fibroblast growth factor in the amniotic fluid.

9. A kit comprising

a composition comprising polymeric microparticles having a diameter between 5 and 10 microns and a zeta potential between −32.8 and −47 mV, the polymeric microparticles having as the sole active agent fibroblast growth factor encapsulated, entrapped, complexed to or dispersed in the microparticles,

wherein the microparticles are formed of alginate, poly(lactic acid)(PLA), poly(glycolic acid)(PGA), poly(lactide-co-glycolide)(PLGA), polyanhydrides, poly(ortho)esters, poly(caprolactone), poly(hydroxyalkanoates), poly(lactide-co-caprolactone), poly(beta-amino)esters(PBAEs) or poly(amine-co-ester)polymers(PACE),

wherein the composition is formulated for infusion or injection into the amniotic sac, and

a needle for delivery of the microparticle formulation into the amniotic sac.

10. The kit of claim 9 wherein the microparticles are in a concentration between 0.01 mg/ml to about 100 mg/ml, about 0.5 mg/ml to about 50 mg/ml, or about 1 mg/ml to about 10 mg/ml.

11. The kit of claim 9 wherein the microparticles have a loading of FGF per mg of particles releasing picograms of FGF into the amniotic fluid.

12. The kit of claim 9 wherein the microparticles are formed of poly(lactic acid) (PLA), poly(glycolic acid)(PGA), poly(lactide-co-glycolide)(PLGA), or alginate.

13. The kit of claim 9 comprising dosage units of 5-10 micron poly(lactic acid)(PLA), poly(glycolic acid)(PGA), or poly(lactide-co-glycolide)(PLGA) microparticles having a loading of fibroblast growth factor producing picogram levels of FGF in the amniotic fluid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2024
From: SALTZMAN, W. MARK; RICCIARDI, ADELE S.; STITELMAN, DAVID H.; FARRELLY, JAMES; BIANCHI, ANTHONY
To: YALE UNIVERSITY
Reel/Frame 066819/0306 →
Continuity (5)
Continuation 16603152
Provisional Application 62481562 · Apr 4, 2017
Provisional Application 62489377 · Apr 24, 2017
Provisional Application 62589275 · Nov 21, 2017
Related Publication 20240207172A1 · Jun 27, 2024
References Cited (400)
US 3266987A · Crowley · 1966 [cited by applicant]
US 3832253A · Palma · 1974 [cited by applicant]
US 3854480A · Zaffaroni · 1974 [cited by applicant]
US 4452775A · Kent · 1984 [cited by applicant]
US 4460563A · Calanchi · 1984 [cited by applicant]
US 4667013A · Reichle · 1987 [cited by applicant]
US 4675189A · Kent · 1987 [cited by applicant]
US 4714680A · Civin · 1987 [cited by applicant]
US 4748034A · Rham · 1988 [cited by applicant]
US 4794000A · Ecanow · 1988 [cited by applicant]
US 4883666A · Sabel · 1989 [cited by applicant]
US 4965204A · Civin · 1990 [cited by applicant]
US 5034506A · Summerton · 1991 [cited by applicant]
US 5061620A · Tsukamoto · 1991 [cited by applicant]
US 5075109A · Tice · 1991 [cited by applicant]
US 5114719A · Sabel · 1992 [cited by applicant]
US 5118528A · Fessi · 1992 [cited by applicant]
US 5133974A · Paradissis · 1992 [cited by applicant]
US 5142047A · Summerton · 1992 [cited by applicant]
US 5176996A · Hogan · 1993 [cited by applicant]
US 5185444A · Summerton · 1993 [cited by applicant]
US 5239660A · Ooi · 1993 [cited by applicant]
US 5354670A · Nickoloff · 1994 [cited by applicant]
US 5356802A · Chandrasegaran · 1994 [cited by applicant]
US 5407686A · Patel · 1995 [cited by applicant]
US 5422251A · Fresco · 1995 [cited by applicant]
US 5436150A · Chandrasegaran · 1995 [cited by applicant]
US 5487994A · Chandrasegaran · 1996 [cited by applicant]
US 5527675A · Coull · 1996 [cited by applicant]
US 5539082A · Nielsen · 1996 [cited by applicant]
US 5601835A · Sabel · 1997 [cited by applicant]
US 5623049A · Lobberding · 1997 [cited by applicant]
US 5643741A · Tsukamoto · 1997 [cited by applicant]
US 5665541A · Miller · 1997 [cited by applicant]
US 5677136A · Simmons · 1997 [cited by applicant]
US 5698546A · Bridger · 1997 [cited by applicant]
US 5714331A · Buchardt · 1998 [cited by applicant]
US 5716827A · Tsukamoto · 1998 [cited by applicant]
US 5736152A · Dunn · 1998 [cited by applicant]
US 5736336A · Buchardt · 1998 [cited by applicant]
US 5739308A · Kandimalla · 1998 [cited by applicant]
US 5750397A · Tsukamoto · 1998 [cited by applicant]
US 5759793A · Schwartz · 1998 [cited by applicant]
US 5773571A · Nielsen · 1998 [cited by applicant]
US 5776744A · Glazer · 1998 [cited by applicant]
US 5786461A · Buchardt · 1998 [cited by applicant]
US 5786571A · Bethel · 1998 [cited by applicant]
US 5854033A · Lizardi · 1998 [cited by applicant]
US 5866361A · Dujon · 1999 [cited by applicant]
US 5932711A · Boles · 1999 [cited by applicant]
US 5945337A · Brown · 1999 [cited by applicant]
US 5962426A · Glazer · 1999 [cited by applicant]
US 6010908A · Gruenert · 2000 [cited by applicant]
US 6140081A · Barbas · 2000 [cited by applicant]
US 6261841B1 · Cohen · 2001 [cited by applicant]
US 6303376B1 · Glazer · 2001 [cited by applicant]
US 6326479B1 · Gildea · 2001 [cited by applicant]
US 6331617B1 · Weeks · 2001 [cited by applicant]
US 6363746B1 · Wei · 2002 [cited by applicant]
US 6422251B1 · Tseng · 2002 [cited by applicant]
US 6441130B1 · Egholm · 2002 [cited by applicant]
US 6453242B1 · Eisenberg · 2002 [cited by applicant]
US 6509323B1 · Davis · 2003 [cited by applicant]
US 6534261B1 · Cox · 2003 [cited by applicant]
US 6610512B1 · Barbas · 2003 [cited by applicant]
US 6632919B1 · Nielsen · 2003 [cited by applicant]
US 6686463B2 · Beigelman · 2004 [cited by applicant]
US 6746838B1 · Choo · 2004 [cited by applicant]
US 6770442B2 · Gildea · 2004 [cited by applicant]
US 6866997B1 · Choo · 2005 [cited by applicant]
US 6919208B2 · Levy · 2005 [cited by applicant]
US 7067617B2 · Barbas · 2006 [cited by applicant]
US 7078389B2 · Glazer · 2006 [cited by applicant]
US 7256275B2 · Coull · 2007 [cited by applicant]
US 7279463B2 · Glazer · 2007 [cited by applicant]
US 7534448B2 · Saltzman · 2009 [cited by applicant]
US 7534449B2 · Saltzman · 2009 [cited by applicant]
US 7550154B2 · Saltzman · 2009 [cited by applicant]
US 7566535B2 · Kmiec · 2009 [cited by applicant]
US 8309356B2 · Glazer · 2012 [cited by applicant]
US 8658608B2 · Glazer · 2014 [cited by applicant]
US 8889117B2 · Mellman · 2014 [cited by applicant]
US 9193758B2 · Ly · 2015 [cited by applicant]
US 9220698B2 · Ault · 2015 [cited by applicant]
US 9272043B2 · Saltzman · 2016 [cited by applicant]
US 9317102B2 · Kanchana · 2016 [cited by applicant]
US 9501364B1 · Bushman · 2016 [cited by applicant]
US 9501365B2 · Nitin · 2016 [cited by applicant]
US 9526136B1 · Ramabhadran · 2016 [cited by applicant]
US 9617074B2 · Hellenbrand · 2017 [cited by applicant]
US 9834945B2 · Crumley · 2017 [cited by applicant]
US 11136597B2 · Saltzman · 2021 [cited by applicant]
US 20020165356A1 · Barbas · 2002 [cited by applicant]
US 20030044978A1 · Young · 2003 [cited by applicant]
US 20030113894A1 · Selden · 2003 [cited by applicant]
US 20030148352A1 · Glazer · 2003 [cited by applicant]
US 20030211612A1 · Seidman · 2003 [cited by applicant]
US 20040006035A1 · Macejak · 2004 [cited by applicant]
US 20040197892A1 · Moore · 2004 [cited by applicant]
US 20040241651A1 · Olek · 2004 [cited by applicant]
US 20060045874A1 · Bedwell · 2006 [cited by applicant]
US 20070154989A1 · Barbas · 2007 [cited by applicant]
US 20070213269A1 · Barbas · 2007 [cited by applicant]
US 20070219122A1 · Glazer · 2007 [cited by applicant]
US 20080050920A1 · Kawahara · 2008 [cited by applicant]
US 20090239789A1 · Saltzman · 2009 [cited by applicant]
US 20090269397A1 · Saltzman · 2009 [cited by applicant]
US 20100151436A1 · Fong · 2010 [cited by applicant]
US 20100172882A1 · Glazer · 2010 [cited by applicant]
US 20110008451A1 · Saltzman · 2011 [cited by applicant]
US 20110145940A1 · Voytas · 2011 [cited by applicant]
US 20110262406A1 · Campo · 2011 [cited by applicant]
US 20110268810A1 · Saltzman · 2011 [cited by applicant]
US 20110293585A1 · Del Campo · 2011 [cited by applicant]
US 20140128570A1 · Ly · 2014 [cited by applicant]
US 20140255384A1 · Frey, II · 2014 [cited by applicant]
US 20140342003A1 · Saltzman · 2014 [cited by applicant]
US 20150057505A1 · Bangera · 2015 [cited by applicant]
US 20150073041A1 · Saltzman · 2015 [cited by applicant]
US 20150118311A1 · Zhou · 2015 [cited by applicant]
US 20150125384A1 · Mellman · 2015 [cited by applicant]
US 20160251477A1 · Cui · 2016 [cited by applicant]
US 20160263875A1 · Ueno · 2016 [cited by applicant]
US 20170000737A1 · Deng · 2017 [cited by applicant]
US 20170266119A1 · Deng · 2017 [cited by applicant]
US 20170283830A1 · Saltzman · 2017 [cited by applicant]
US 20200113821A1 · Saltzman · 2020 [cited by applicant]
US 20200308590A1 · Glazer · 2020 [cited by applicant]
EP 0253193 · 1988 [cited by applicant]
EP 0266099 · 1988 [cited by applicant]
EP 0375408 · 1990 [cited by applicant]
EP 2754684 · 2014 [cited by applicant]
EP 3388517 · 2018 [cited by applicant]
GB 929401 · 1963 [cited by applicant]
WO 9220698 · 1992 [cited by applicant]
WO 93012096 · 1993 [cited by applicant]
WO 9317102 · 1993 [cited by applicant]
WO 93017102 · 1993 [cited by applicant]
WO 95001364 · 1995 [cited by applicant]
WO 95013650 · 1995 [cited by applicant]
WO 1995001364 · 1995 [cited by applicant]
WO 9526136 · 1995 [cited by applicant]
WO 9602558 · 1996 [cited by applicant]
WO 96039195 · 1996 [cited by applicant]
WO 1996004000 · 1996 [cited by applicant]
WO 9617074 · 1996 [cited by applicant]
WO 96017074 · 1996 [cited by applicant]
WO 96040271 · 1996 [cited by applicant]
WO 96040898 · 1996 [cited by applicant]
WO 9834945 · 1998 [cited by applicant]
WO 98034945 · 1998 [cited by applicant]
WO 98053059 · 1998 [cited by applicant]
WO 0022113 · 2000 [cited by applicant]
WO 0022114 · 2000 [cited by applicant]
WO 0125419 · 2001 [cited by applicant]
WO 2002010142 · 2002 [cited by applicant]
WO 2003016496 · 2003 [cited by applicant]
WO 2003052071 · 2003 [cited by applicant]
WO 2005108622 · 2005 [cited by applicant]
WO 2008086529 · 2008 [cited by applicant]
WO 2010123983 · 2010 [cited by applicant]
WO 2011053989 · 2011 [cited by applicant]
WO 2011072246 · 2011 [cited by applicant]
WO 2011133802 · 2011 [cited by applicant]
WO 2011133803 · 2011 [cited by applicant]
WO 2012085554 · 2012 [cited by applicant]
WO 2012138955 · 2012 [cited by applicant]
WO 2013082529 · 2013 [cited by applicant]
WO 2013176772 · 2013 [cited by applicant]
WO 2014018423 · 2014 [cited by applicant]
WO 2014110020 · 2014 [cited by applicant]
WO 2015148716 · 2015 [cited by applicant]
WO 2015172149 · 2015 [cited by applicant]
WO 2015172153 · 2015 [cited by applicant]
WO 2016081621 · 2016 [cited by applicant]
WO 2016183209 · 2016 [cited by applicant]
WO 2016183217 · 2016 [cited by applicant]
WO 2017143042 · 2017 [cited by applicant]
WO 2017143061 · 2017 [cited by applicant]
WO 2018175927 · 2018 [cited by applicant]
WO 2018187493 · 2018 [cited by applicant]
Khaboushan et al., Stem Cell Reviews and Reports, 2022, 18: 752-767. [cited by examiner]
Watanabe et al.,Tissue Engineering, 2011, 17: 1099-1110. [cited by examiner]
Wiltsey et al., Acta Biomaterialia, 2015, 16: 71-80. [cited by examiner]
Watanabe et al., Tissue Engineering: Part A, 2010, 16: 1645-1655. [cited by examiner]
Chandrasekar et al., Food Hydrocolloids, 2017, 69: 301-307. [cited by examiner]
Formiga et al., J. Conrol. Rel., 2014, 173: 132-139. [cited by examiner]
Zhou et al., Int. J. Pharm., 2009, 37: 197-195. [cited by examiner]
Oshiro et al., Int. J. Polym. Sci., 2015, pp. 1-7. [cited by examiner]
Murata, et al., “Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice”, J. Control. Release, 126(3):246-54 (2008). [cited by applicant]
Capecchi, “Altering the genome by homologous recombination,” Science 244(4910): 1288-1292 (1989). [cited by applicant]
Orson, et al., “Oligonucleotide inhibition of IL2R alpha mRNA transcription by promoter region collinear triplex formation in lymphocytes”, Nucleic Acids Res. 19:3435-41 (1991). [cited by applicant]
Goncz, et al., “Small fragment homologous replacement-mediated modification of genomic beta-globin sequences in human hematopoietic stem/progenitor cells”, Oligonucleotides, 16:213-24 (2006). [cited by applicant]
Jagodzinski, “Enhanced human immunodeficiency virus infection in macrophages by high-molecular-weight dextran sulfate is associated with conformational changes of gp120 and expression of the CCR5 receptor”, Viral Immuno… [cited by applicant]
Sancar, “DNA excision repair,” Annu. Rev. Biochem. 65: 43-81 (1996). [cited by applicant]
Sterchak, et al., “Uncharged stereoregular nucleic acid analogs. 1. Synthesis of a cytosine-containing oligomer with carbamate internucleoside linkages”, Organic Chem., 52:4202-6 (1987). [cited by applicant]
Warren, et al., Coordinated Transcription-Dependent Redistribution, Journal of Cellular Biochemistry, Supplement 21B:141 (1995). [cited by applicant]
Abes, et al., “Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates”, J. Controll. Rel., 110:595-604 (2006). [cited by applicant]
Allison, et al., “The C-Terminal Domain of the Largest Subunit of RNA Polymerase II of [cited by applicant]
Asensio, et al., “The Contribution of Cytosine Protonation to the Stability of Parallel DNA Triple Helices”, J. Mol. Biol., 275(5): 811-822 (1998b). [cited by applicant]
Baron, et al., “Localization of the Centrin-Related 165,000-M.sub.r Protein of PtK.sub.2 Cells During the Cell Cycle,” Cell Motil. and the Cytoskel. 18:1-14 (1991). [cited by applicant]
Baumann, et al., “Role of the human RAD51 protein in homologous recombination and double-stranded-break repair”, Trends Biochem Sci, 23(7):247-251 (1998). [cited by applicant]
Belousov, et al., “Triplex targeting of a native gene in permeabilized intact cells: covalent modification of the gene for the chemokine receptor CCR5”, Nucleic Acids Res., 26(5): 1324-1328 (1998). [cited by applicant]
Bennett and Davis, “Erythrocyte ankyrin: Immunoreactive analogues are associated with mitotic structures in cultured cells and with microtubules in brain”, Proc. Natl. Acad. Sci. USA., 78:7550-7554 (1981). [cited by applicant]
Braasch, et al., “Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA”, Chem. Biol., 8(1):1-7 (2001). [cited by applicant]
Bredberg, et al., “Psoralen adducts in a shuttle vector plasmid propagated in primate cells: high mutagenicity of DNA cross-links”, Carcinogenesis, 8(12):1923-1927 (1987). [cited by applicant]
Brenneman, et al., “Stimulation of intrachromosomal homologous recombination in human cells by electroporation with site-specific endonucleases”, Proc. Natl. Acad. Sci. USA, 93(8):3608-3612 (1996). [cited by applicant]
Carrington, et al., “Novel alleles of the chemokine-receptor gene CCR5.”, Am. J. Hum. Genet., 61:1261-1267 (1997). [cited by applicant]
Chan, et al., “Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming oligonucleotide”, J. Biol. Chem., 274(17):11541-11548 (1999). [cited by applicant]
Chen, et al., “Ethyl carbamate metabolism: in vivo inhibitors and in vitro enzymatic systems.”, Drug Metab. Dispos., 18:815 (1990). [cited by applicant]
Chen, et al., “In Vivo Expression of Single-Stranded DNA in Mammalian Cells with DNA Enzyme Sequences Targeted to C-raf,” Antisense Nucleic Acid Drug Dev. 10:415-422 (2000). [cited by applicant]
Cuenoud, et al., “Dual recognition of double-stranded DNA by 2′-aminoethoxy-modified oligonucleotides”, Angew. Chem. Int. Ed., 37:1288-1291 (1998). [cited by applicant]
Dagle, et al., “Positively charged oligonucleotides overcome potassium-mediated inhibition of triplex DNA formation”, Nucleic Acids Res., 24(11):2143-9 (1996). [cited by applicant]
Dahmus, “Phosphorylation of Eukaryotic DNA-dependent RNA Polymerase”, J. Biol. Chem., 256:3332-3339 (1981). [cited by applicant]
Datta, et al., “Triplex-induced Recombination in Human Cell-free Extracts,” J. Biol. Chem., 276:18018-18023 (2001). [cited by applicant]
Egholm, et al., “Efficient pH-independent sequence-specific DNA binding by pseudoisocytosine-containing bis-PNA.”, Nucl. Acids Res., 23(2):217-222 (1995). [cited by applicant]
Fakan & Bernhard, “Localization of Rapidly and Slowly Labelled Nuclear RNA as Visualized by High Resolution Autoradiography,” Exp. Cell Res. 67:129-141 (1971). [cited by applicant]
Fakan & Puvion, “The Ultrastructural Visualization of Nucleolar and Extranucleolar RNA Synthesis and Distribution,” Int. Rev. Cytol . . . 65:255-99 (1980). [cited by applicant]
Fakan, et al., “Localization and Characterization of Newly Synthesized Nuclear RNA in Isolated Rat Hepatocytes,” Exp. Cell. Res. 99:155-164 (1976). [cited by applicant]
Faria, et al., “Targeted Inhibition of Transcription Elongation in Cells Mediated by Triplex-Forming Oligonucleotides,” Proc. Natl. Acad. Sci. USA, 97: 3862-3867 (2000). [cited by applicant]
Faruqi, et al., “Triple-helix formation induces recombination in mammalian cells via a nucleotide excision repair-dependent pathway”, Mol. Cell. Bio., 20(3):990-1000 (2000). [cited by applicant]
Gasparro, et al., “Photoactivatable antisense DNA: suppression of ampicillin resistance in normally resistant [cited by applicant]
Gasparro, et al., “Site-specific targeting of Psoralen Photoadducts with a Triple Helix-Forming Oligonucleotide: Characterization of Psoralen Monoadduct and Crosslink Formation”, Nucl. Acids Res., 22(14):2845-2852 (1994… [cited by applicant]
Gasparro, et al., “Rapid and sensitive analysis of 8-methoxypsoralen in plasma,” J. Invest. Derm., 90:234-236 (1988). [cited by applicant]
Gerace, et al., “Immunocytochemical Localization of the Major Polypeptides of the Nuclear Pore Complex—Lamina Fraction”, J. Cell Biol., 79:546-566 (1978). [cited by applicant]
Gia, et al., “Sequence specificity of psoralen photobinding to DNA: a quantitative approach,” Biochemistry 31:11818-11822 (1992). [cited by applicant]
Giovannangeli, et al., “Triplex-forming molecules for modulation of DNA information processing,” Curr. Opin. Mol. Ther. 2(3): 288-296 (2000). [cited by applicant]
Glazer, et al., “Detection and Analysis of UV-induced Mutations in Mammalian Cell DNA Using A Phage Suttle Vector”, Proc. Natl. Acad. Sci., 83:1041-1044 (1986). [cited by applicant]
Goncz, et al., “Site-directed alteration of genomic DNA by small-fragment homologous replacement”, Methods Mol. Biol., 133:85-89 (2000). [cited by applicant]
Gordenin, et al., “Yeast ARMs (DNA at-risk motifs) can reveal sources of genome instability.”, Mutat. Res., 400(1-2):45-58 (1998). [cited by applicant]
Gorman, et al., “Stable Alteration of Pre-mRNA Splicing Patterns by Modified U7 Small Nuclear RNAs,” Proc. Natl. Acad. Sci. USA, 95: 4929-4934 (1998). [cited by applicant]
Grigoriev, et al., “Oligodeoxynucleotide-directed Photo-induced Cross-linking of HIV Proviral DNA via Triple-helix Formation,” Nucleic Acids Research, 20(16):4275-4281 (1992A). [cited by applicant]
Hanson, et al., “Analysis of biological selections for high-efficiency gene targeting”, Mol. Cell. Biol., 15(1):45-51 (1995). [cited by applicant]
Harding, “NMR Studies on YSPTSPSY: Implications for the Design of DNA Bisintercalators,” Journal of Medicinal Chemistry, 35:4658-4664 (1992). [cited by applicant]
Hartley, et al., “Electrophoretic and chromatographic separation methods used to reveal interstrand crosslinking of nucleic acids”, J. Chromatogr., 618(1-2):277-88 (1993). [cited by applicant]
Havre & Glazer, “Targeted mutagenesis of simian virus 40 DNA mediated by a triple helix-forming oligonucleotide”, J. Virol., 67(12):7324-7331 (1993a). [cited by applicant]
Havre, et al., “Targed Mutagenesis of DNA Using Triple Helix-forming Oligonucleotides Linked to Psoralen”, Proc. Natl. Acad. Sci. USA, 90(16):7879-7883 (1993b). [cited by applicant]
Helene, “Sequence-selective recognition and cleavage of double-helical DNA”, Curr. Opinion Biotechnology, 4:29-36 (1993). [cited by applicant]
Helene, et al., “The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides,” Anticancer Drug Des. 6(6):569-84 (1991). [cited by applicant]
Henry & Hodge, “Nuclear Matrix: A Cell-Cycle-Dependent Site of Increased Intranuclear Protein Phosphorylation,” Eur. J. Biochem. 133:23-29 (1983). [cited by applicant]
Hirt, et al., “Selective extraction of polyoma DNA from infected mouse cell cultures” J. Mol. Biol. 26:365-369 (1967). [cited by applicant]
Huang, et al., “Functional silencing of hepatic microsomal glucose-6-phosphatase gene expression in vivo by adenovirus-mediated delivery of short hairpin RNA”, FEBS Lett., 558(1-3):69-73 (2004). [cited by applicant]
Iverson, et al., “In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue,” Anticancer Drug Des. 6(6):531-8 (1991). [cited by applicant]
Jackson, et al., “Visualization of focal sites of transcription within human nuclei”, EMBO, 12:1059-1065 (1993). [cited by applicant]
Jakubczak, et al., “Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage lambda transgene target”, Proc. Natl. Acad. Sci. USA, 93:… [cited by applicant]
James, et al., “Towards gene-inhibition therapy: a review of progress and prospects in the field of antiviral antisense nucleic acids and ribozymes”, Antiviral Chemistry & Chemotherapy, 2:191-214 (1991). [cited by applicant]
Jepsen, et al., “LNA-antisense rivals siRNA for gene silencing”, Curr. Opin. Drug Discov. Devel., 7(2):188-194 (2004). [cited by applicant]
Khiat, et al., “Structural Differences Between the Free and Bound States of DNA-Bisintercalating Peptide YSPTSPSY”, Journal of Medicinal Chemistry, 39(21):2495 (1996). [cited by applicant]
Kitagawa, et al., “Enzyme coupled immunoassay of insulin using a novel coupling reagent.”, J. Biochem., 79:233-236 (1976). [cited by applicant]
Koppelhus, et al., “Cellular delivery of peptide nucleic acid (PNA)” Adv. Drug Deliv. Rev., 55(2):267-280 (2003). [cited by applicant]
Kuhn, et al., “An experimental study of mechanism and specificity of peptide nucleic acid (PNA) binding to duplex DNA.”, J. Mol. Biol., 286(5):1337-1345 (1999). [cited by applicant]
Lacroix, et al., “Triplex formation by oligonucleotides containing 5-(1-propynyl)-2′-deoxyuridine: decreased magnesium dependence and improved intracellular gene targeting”, Biochemistry, 38(6):1893-1901(1999). [cited by applicant]
Laemmli, “Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4”, Nature, 227:680-685 (1970). [cited by applicant]
Lassner, et al., “Targeting of T7 RNA polymerase to tobacco nuclei mediated by an SV40 nuclear location signal”, Plant Mol Biol., 17(2):29-34 (1991). [cited by applicant]
Lee and Greenleaf, “A protein kinase that phosphorylates the C-terminal repeat domain of the largest subunit of RNA polymerase II,” Proc. Natl. Acad. Sci. U.S.A. 86:3624-28 (1989). [cited by applicant]
Letai, et al., “Specificity in formation of triple-stranded nucleic acid helical complexes: studies with agarose-linked polyribonucleotide affinity columns”, Biochemistry, 27:9108-9112 (1988). [cited by applicant]
Lin, et al., “Repair of double-stranded DNA breaks by homologous DNA fragments during transfer of DNA into mouse L Cells,” Molecular and Cellular Biology 10:113-119 (1990). [cited by applicant]
Lin, et al., “Extrachromosomal recombination in mammalian cells as studied with single- and double-stranded DNA substrates”, Mol. Cell. Biol., 7(1):129-140 (1987). [cited by applicant]
Lind, et al., “Structural characteristics of 2′-O-(2-methoxyethyl)-modified nucleic acids from molecular dynamics simulations”, Nucleic Acids Res., 26(16):3694-799 (1998). [cited by applicant]
Liu, et al., “New procedures for preparation and isolation of conjugates of proteins and a synthetic copolymer of D-amino acids and immunochemical characterization of such conjugates.”, Biochem., 18:690-693 (1979). [cited by applicant]
Luo, et al., “High-frequency intrachromosomal gene conversion induced by triplex-forming oligonucleotides microinjected into mouse cells”, Proc. Natl. Acad. Sci. U.S.A., 97(16):9003-9008 (2000). [cited by applicant]
Ma, et al., “Nuclease-resistant external guide sequence-induced cleavage of target RNA by human ribonuclease P”, Antisense Nucleic Acid Drug Dev., 8(5):415-26 (1998). [cited by applicant]
Majumdar, et al., “Cell cycle modulation of gene targeting by a triple helix-forming oligonucleotide”, J. Biol. Chem., 278(13):11072-7 (2003A). [cited by applicant]
Majumdar, et al., “Targeted gene knockout mediated by triple helix forming oligonucleotides”, Nat. Genet., 20:212-214 (1998). [cited by applicant]
Mergny, et al., “Sequence specificity in triple-helix formation: experimental and theoretical studies of the effect of mismatches on triplex stability.”, Biochemistry, 30(40):9791-9798 (1991). [cited by applicant]
Mirabelli, et al., “In Vitro and in vivo pharmacologic activities of antisense oligonucleotides”, Anticancer Design, 6:647-661 (1991). [cited by applicant]
Myhr, “Validation studies with Muta Mouse: a transgenic mouse model for detecting mutations in vivo”, Environ. Mol. Mutagen, 18:308-315(1991). [cited by applicant]
Narayanan, et al., “Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2”, Proc. Natl. Acad. Sci. USA, 94:3122-3127 (1997). [cited by applicant]
Nickerson, et al., “A Normally Masked Nuclear Matrix Antigen That Appears at Mitosis on Cytoskeleton Filaments Adjoining Chromosomes, Centrioles, and Midbodies”, J. Cell. Biol., 116:977-987 (1992). [cited by applicant]
Noonberg, et al., “In Vivo Generation of Highly Abundant Sequence-Specific Oligonucleotides for Antisense and Triplex Gene Regulation,” Nucleic Acids Res., 22:2830-2836 (1994). [cited by applicant]
Nyce and Metzger, “DNA antisense therapy for asthma in an animal model”, Nature, 385(6618):721-5 (1997). [cited by applicant]
Obika, et al., “2′-O,4′-C-Methylene bridged nucleic acid (2′,4′-BNA): synthesis and triplex-forming properties”, Bioorg. Med. Chem., 9(4):1001-1011 (2001). [cited by applicant]
O'Keefe, et al., “Disruption of Pre-mRNA Splicing In Vivo Results in Reorganization of Slicing Factors”, J. Cell Biol., 124:249-260 (1994). [cited by applicant]
Park, et al., “Formation of a ternary complex by human XPA, ERCC1, and ERCC4(XPF) excision repair proteins”, Proc. Natl. Acad. Sci. USA, 91:5017-5021 (1994). [cited by applicant]
Pattanayek, et al., “Structural rationalization of a large difference in RNA affinity despite a small difference in chemistry between two 2′-O-modified nucleic acid analogues”, J. Am. Chem. Soc., 126(46):15006-15007 (20… [cited by applicant]
Postel, et al., “Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in Hela cells, thereby reducing c-myc mRNA levels.”, Proc. Natl. Acad. Sci. USA, 88(18):8227-8231 (1991). [cited by applicant]
Price & Pettijohn, “Redistribution of the Nuclear Mitotic Apparatus Protein (NuMA) during Mitosis and Nuclear Assembly”, Exp. Cell Res., 166:292-311 (1986). [cited by applicant]
Puri, et al., “Minimum number of 2′-O-(2-aminoethyl) residues required for gene knockout activity by triple helix forming oligonucleotides”, Biochemistry, 41(24):7716-7724 (2002). [cited by applicant]
Raha, et al., “Mutagenesis by Third-Strand-Directed Psoralen Adducts in Repair-Deficient Human Cells: High Frequency and Altered Specgrum in a Xeroderma Pigmentosum Variant,” Proc. Natl. Acad. Sci. USA, 93(7):2941-2942 … [cited by applicant]
Roberts, et al., “Stability and Properties of Double and Triple Helices: Dramatic Effects of RNA or DNA Backbone Composition,” Science 258: 1463-1466 (1992). [cited by applicant]
Rooney and Moore, “Antiparallel, intramolecular triplex DNA stimulates homologous recombination in human cells,” Proc. Natl. Acad. Sci. USA, 92:2141-2144 (1995). [cited by applicant]
Sambrook, et al., Molecular Cloning: A Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press: New York (1989). [cited by applicant]
Seipel, et al., “Basal Components of the Transcription Apparatus (RNA Polymerase II, TATA-binding Protein) Contain Activation Domains: Is Repetitive C-Terminal Domain (CTD) of RNA Polymerase II a Portable Enhancer Domai… [cited by applicant]
Shevelev, et al., “Potential Triple Helix-Mediated Inhibition of IGF-I Gene Expression Significantly Reduces Tumorigenicity of Gliolastoma in an Animal Model,” Cancer Gene Therapy, 4:105-112 (1997). [cited by applicant]
Sibghat-Ullah, et al., “Human nucleotide excision repair in vitro: repair of pyrimidine dimers, psoralen and cisplatin adducts by HeLa cell-free extract”, Nucl. Acids Res., 17:4471-4484 (1989). [cited by applicant]
Sidransky, et al., “Identification of p53 gene mutations in bladder cancers and urine samples.”, Science 252:706-709 (1991). [cited by applicant]
Singleton and Dervan, “Influence of pH on the Equilibrium Association Constants for Oligodeoxyribonucleotide-Directed Triple Helix Formation at Single DNA Sites”, Biochemistry, 31:10995-11003 (1992). [cited by applicant]
Smith, et al., “Alterations in chromatic Conformation Are Accompanies by Reorganization of Nonchromatin Domains That Contain U-snRNP Protein p28 and Nuclear Protein p107”, J. Cell. Biol., 101:560-567 (1985). [cited by applicant]
Steinberger, et al., “Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion.”, Proc. Natl. Acad. Sci. USA., 97(2):805… [cited by applicant]
Takasugi, et al., “Sequence-specific photo-induced cross-linking of the two strands of double-helical DNA by a psoralen covalently linked to a triple helix-forming oligonucleotide.”, Proc. Natl. Acad. Sci. USA, 88(13):5… [cited by applicant]
Talmadge, “The pharmaceutics and delivery of therapeutic polypeptides and proteins”, Adv. Drug Del. Rev., 10:247-299 (1993). [cited by applicant]
Thibodeau and Vincent, “Monoclonal Antibody CC-3 Recognizes Phosphorproteins in Interphase and Mitotic Cells”, Experimental Cell Research, 195:145-153 (1991). [cited by applicant]
Towbin, et al., “Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications”, Proc. Natl. Acad. Sci USA., 76:4350-4354 (1979). [cited by applicant]
Vasquez, et al., “Specific mutations induced by triplex-forming oligonucleotides in mice”, Science, 290:530-533 (2000). [cited by applicant]
Vasquez, et al., “Triplex-directed modification of genes and gene activity.”, Trends Biochem. Sci., 23(1):4-9 (1998). [cited by applicant]
Wang, et al., “Altered Repair of Targeted Psoralen Photoadducts in the Context of an Oligonucleotide-mediated Triple Helix”, J. Biol. Chem., 270(22):22595-22601(1996a). [cited by applicant]
Wansink, et al., “Fluorescent Labeling of Nascent RNA Reveals Transcription by RNA Polymerase II in Domains Scattered Throughout the Nucleus,” J. Cell. Biol., 122:283-293 (1993). [cited by applicant]
Warren and Nelson, “Nonmitogenic Morphoregulatory Action of pp60.sup.v-src on Multicellular Epithelial Structures”, Mol. Cell. Biol., 7:1326-1337 (1987). [cited by applicant]
Warren, et al., “Cytostellin: a novel. highly conserved protein that undergoes continuous redistribution during the cell cycle”, J. Cell Sci., 103:381-388 (1992). [cited by applicant]
Whitesell, et al., “Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system,” Proc. Natl. Acad. Sci. U S… [cited by applicant]
Wood, et al., “The Effect of Volume and Temperature on the Energy and Entropy of Pure Liquids”, J. Am. Chem. Soc., 79:2023-2024 (1957). [cited by applicant]
Xing and Lawrence, “Higher Level Organization of Individual Gene Transcription and RNA Splicing,” Science 259:1326-1330 (1993). [cited by applicant]
Yang, et al., “Nu-MA: An Unusually Long Coiled-Coil Related Protein in the Mammalian Nucleus,” J. Cell Biol. 116:1303-1317 (1992). [cited by applicant]
Zendegui, et al., “In vivo stability and kinetics of absorption and disposition of 3′ phosphopropyl amine oligonucleotides.”, Nucleic Acids Res., 20(2):307-314 (1992). [cited by applicant]
Zielke, et al., “Repetitive synchronization of human lymphoblast cultures with excess thymidine”, Methods Cell Biol., 8(0):107-121 (1974). [cited by applicant]
Zon and Geiser, “Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions,” Anticancer Drug Des. 6(6):539-68 (1991). [cited by applicant]
Horne, et al., “Recognition of Mixed-Sequence Duplex DNA by Alternate-Strand Triple-Helix Formation”, J. Am. Chem. Soc., 112:2435-2437 (1990). [cited by applicant]
Izvolsky, et al., “Sequence-specific protection of duplex DNA against restriction and methylation enzymes by pseudocomplementary PNAs”, Biochemistry, 10908-10913 (2000). [cited by applicant]
Knauert, et al., “Triplex-stimulated intermolecular recombination at a single-copy genomic target”, Mol. Therapy, 14:392-400 (2006). [cited by applicant]
Lohse, et al., “Double duplex invasion by peptide nucleic acid: a general principle for sequence-specific targeting of double-stranded DNA”, Proc. Natl. Acad. Sci. USA, 96:11804-11808 (1999). [cited by applicant]
Lorenz, et al., “Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells”, Bioorg. Med. Chem. Lett., 14(19):4975-4977 (2004). [cited by applicant]
Olsen, et al., “Genomic sequence correction by single-stranded DNA oligonucleotides: role of DNA synthesis and chemical modifications of the oligonucleotide ends”, J. Gene Med., 7:1534-1544 (2005). [cited by applicant]
Urnov, et al., “Highly efficient endogenous human gene correction using designed zinc-finger nucleases”, Nature, 435:646-651 (2005). [cited by applicant]
Vasquez, et al., “Manipulating the mammalian genome by homologous recombination”, Proc. Natl. Acad. Sci. USA, 98:8403-8410 (2001). [cited by applicant]
Wu, et al., “Increased efficiency of oligonucleotide-mediated gene repair through slowing replication fork progression”, Proc. Natl. Acad. Sci. USA, 102:2508-2513 (2005). [cited by applicant]
Rump, et al., “Modification of the plasma clearance and liver uptake of steroid ester-conjugated oligodeoxynucleotides by association with (lactosylated) low-density lipoprotein”, Biochem. Pharmacol., 59(11):1407-1416 (… [cited by applicant]
Braden, et al., “Polymeric nanoparticles for sustained down-regulation of annexin A2 lead to reduction in proliferation and migration of prostate cancer cells”, Journal of Biomedical Nanotechnology 3:148-159 (2007). [cited by applicant]
Bramwell, et al., “Particulate delivery systems for biodefense subunit vaccines”, Adv. Drug Deliv. Rev., 57(9):1247-65 (2005). [cited by applicant]
Conner and Schmid, “Regulated portals of entry into the cell”, Nature 422:37-44 (2003). [cited by applicant]
Desai, et al., “The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent”, Pharm. Res., 14(11):1568-73 (1997). [cited by applicant]
Fahmy, et al., “Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting”, Biomaterials, 26: 5727-5736 (2005). [cited by applicant]
Jiang, et al., “Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens”, Adv. Drug Deliv. Rev., 57(3):391-410 (2005). [cited by applicant]
Khan, A. et al., “Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies”, J Drug Target, 12:393-404 (2004). [cited by applicant]
Adzick, “Fetal myelomeningocele: natural history, pathophysiology, and in-utero intervention”, Seminars in fetal & neonatal medicine, 15(1):9-14 (2010). [cited by applicant]
Adzick, et al., “A randomized trial of prenatal versus postnatal repair of myelomeningocele”, The New England Journal Of Medicine, 364(11):993-1004 (2011). [cited by applicant]
Akinc, et al., “Synthesis of poly(beta-amino ester)s optimized for highly effective gene delivery”, Bioconjug Chem., 14:979-88 (2003). [cited by applicant]
Alton, et al., “Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial”, Lancet Respir Med., 3(9):684-91 (2015). [cited by applicant]
Ryan, et al., “Knockout-transgenic mouse model of sickle cell disease.” Science., 278(5339):873-6 (1997). [cited by applicant]
Sahu, et al., “Synthesis and characterization of conformationally preorganized, (R)-diethylene glycol-containing γ-peptide nucleic acids with superior hybridization properties and water solubility”, J. Org. Chem., 76:56… [cited by applicant]
Rodriguez, et al., “Minimal “Self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles”, Science, 339:971-5 (2013). [cited by applicant]
Gruenert, et al., “Established cell lines used in cystic fibrosis research”, J Cystic Fibros, 3 (Suppl 2):191-6 (2004). [cited by applicant]
Genbank accession No. U01317.1—“Human beta globin region on chromosome 11”,42 pages, first appeared Feb. 18, 1994, updated Jan. 9, 2012, accessed Aug. 9, 2017. [cited by applicant]
Fields, et al., “Modified poly(lactic-co-glycolic acid) nanoparticles for enhanced cellular uptake and gene editing in the lung”, Adv Healthc Mater., 4(3):361-6 (with supporting information) (2015). [cited by applicant]
Wick, et al., “Barrier capacity of human placenta for nanosized materials”, Enviro Health Perspectives, 118(3):432-6 (2010). [cited by applicant]
Zhou, et al., “Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery”, Nat Mater., 11(1):82-90 (2012). [cited by applicant]
Tatokoro, et al., “Heat shock protein 90 targeting therapy: state of the art and future perspective”, EXCLI J., 14:48-58 (2015). [cited by applicant]
Sugiyama and Kittaka, “Chiral peptide nucleic acids with a substituent in the N-(2-aminoethy)glycine backbone”, Molecules, 18:287-310 (2013). [cited by applicant]
Weber and Ryan, “ATM and ATR as therapeutic targets in cancer”, Pharmacol Ther., 149:124-38 (2015). [cited by applicant]
Zeiher, et al., “A mouse model for the delta F508 allele of cystic fibrosis”, J Clin Invest., 96:2051-64 (1995). [cited by applicant]
Yuan, et al., “siRNA drug delivery by biodegradable polymeric nanoparticles”, J. Nanosci. Nanotechnol., 6:2821-8 (2006). [cited by applicant]
Yin, “Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype”, Nat Biotechnol., 32(6):551-3 (2014). [cited by applicant]
Walkley, “Pathogenic cascades in lysosomal disease—Why so complex”, J. Inherit. Metab. Dis., 32(2):181-9 (2009). [cited by applicant]
Smith, et al., “The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer”, Adv Cancer Res., 108:73-112 (2010). [cited by applicant]
Singer, et al., “Electronic barcoding of a viral gene at the single-molecule lever”, Nano Ltrs., 12:1722-8 (2012). [cited by applicant]
Schleifman, et al., Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids Chem Biol., 18:1189-98 (2011). [cited by applicant]
Sargent, et al., “Oligo/polynucleotide-based gene modification: strategies and therapeutic potential”, Oligonucleotides, 21(2):55-75 (2011). [cited by applicant]
Yu, et al., “Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro”, PLoS One., 6:e24077 (2011). [cited by applicant]
Von Bismarck, et al., “IKK NBD peptide inhibits LPS induced pulmonary inflammation and alters sphingolipid metabolism in a murine model”, Pulm Pharmacol Ther., 25(3):228-35 (2012). [cited by applicant]
Staretz-Chacham, et al., “Lysosomal storage disorders in the newborn”, Pediatrics, 123(4):1191-207 (2009). [cited by applicant]
Sinn, et al., “Lentiviral vector gene transfer to porcine airways”, Mol Ther Nucleic Acids, 1:e56 (2012). [cited by applicant]
Yamano, et al., “Modified Tat peptide with cationic lipids enhances gene transfection efficiency via temperature-dependent and caveolae-mediated endocytosis”, J Control Release, 152:278-85 (2011). [cited by applicant]
Wang, et al., “The sustained-release behavior and in vitro and in vivo transfection of pEGFP-loaded core-shell-structured chitosan-based composite particles”, Intl J Namomed., 9:4965-78 (2014). [cited by applicant]
UniProtKB—21581(SCF_RAT), 7 pages, first appeared May 1, 1991, updated May 10, 2017, accessed Aug. 11, 2017. [cited by applicant]
Vasquez, et al., “Human XPA and RPA DNA repair proteins participate in specific recognition of triplex-induced helical distortions”, PNAS, 99:5848-53 (2002). [cited by applicant]
UniProtKB—P21583 (SCF_Human), 10 pages, first appeared May 1, 1991, updated May 10, 2017, accessed Aug. 11, 2017. [cited by applicant]
Woodrow, et al., “Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA”, Nat Mater, 8:526-33 (2009). [cited by applicant]
Rivera-Torres, et al., “The position of DNA cleavage by TALENs and cell synchronization influences the frequency of gene editing directed by single-stranded oligonucleotides”, Plos One, 9(5):e96483 1-8 (2014). [cited by applicant]
Reay, et al., “Full-length dystrophin gene transfer to the mdx mouse in utero”, Gene Therapy, 15:531-6 (2008). [cited by applicant]
Recombinant Rat SCF (Stem Cell Factor) Accession No. P2158,1 Catalog No. 300-32) accessed Aug. 11, 2017. [cited by applicant]
Rapireddy, et al., “Strand invasion of mixed-sequence, double-helical B-DNA by γ-peptide nucleic acids containing G-clamp nucleobases under physiological conditions”, Biochemistry, 50(19):3913-8 (2011). [cited by applicant]
Ramachandran, et al., “A microRNA network regulates expression and biosynthesis of wild-type and DeltaF508 mutant cystic fibrosis transmembrane conductance regulator”, PNAS, 109:13362-7 (2012). [cited by applicant]
Pászty, et al., “Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease.” Science, 278(5339):876-8 (1997). [cited by applicant]
Oakland, et al., “Advances in cell and gene-based therapies for cystic fibrosis lung disease”, Mol Ther., 20:1108-15 (2012). [cited by applicant]
Nielsen, et al., “Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide”, Science (Washington, D.C., 1883-), 254:1497-1500 (1991). [cited by applicant]
Nie, et al., “Lysine-based peptide-functionalized PLGA foams for controlled DNA delivery”, J Control Release, 138:64-70 (2009). [cited by applicant]
NCBI Reference Sequence: NG_008103.1), “ [cited by applicant]
NCBI Reference Sequence: NG_007119.1), “ [cited by applicant]
Miller, et al., “A TALE nuclease architecture for efficient genome editing”, Nature Biotechnol 29: 143 (2011). [cited by applicant]
Mcneer, “Nanoparticles for site specific genome editing”, Dissertation presented to the Facility of Graduate School of Yale University, 154 pages, May 2013. [cited by applicant]
Miccio, et al., “In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia”, PNAS, 105:10547-52 (2008). [cited by applicant]
Mcneer, et al., “Correction of F508DEL CFTR using nanoparticles delivering triplex-forming peptide nucleic acid molecules”, Nat Commun. 6(6952):1-25 (2015c). [cited by applicant]
Mcneer, et al., “Polymer delivery systems for site-specific genome editing”, J Control Release, 155(2): 312-316 (2011b). [cited by applicant]
Mcneer, et al., “Nanoparticles Deliver Triplex-forming PNAs for Site-specific Genomic Recombination in CD34+ Human Hematopoietic Progenitors”, Mol Ther., 19(1):172-80 (2011a). [cited by applicant]
Magzoub, et al., “N-terminal peptides from unprocessed prion proteins enter cells by micropinocytosis”, Biochem Biophys Res Commun., 348:379-85 (2006). [cited by applicant]
Mali, et al., “RNA-guided human genome engineering via Cas9”, Science, 339:823-6 (2013). [cited by applicant]
Luo, et al., “Controlled DNA delivery systems”, Pharm Res, 16:1300-08 (1999). [cited by applicant]
Lynn, et al., “Degradable Poly(β-amino esters): Synthesis, Characterization, and Self-Assembly with Plasmid DNA”, J Am Chem Soc., 122(44):10761-10768 (2000). [cited by applicant]
Little, et al., “Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines”, PNAS, 101:9534-9 (2004). [cited by applicant]
Little, et al., “Formulation and characterization of poly (beta amino ester) microparticles for genetic vaccine delivery”, J Control Release, 107:449-62 (2005). [cited by applicant]
Luens, et al., “Thrombopoietin, kit ligand, and flk2/flt3 ligand together induce increased numbers of primitive hematopoietic progenitors from human CD34+Thy-1+Lin-cells with preserved ability to engraft SCID-hu bone”, … [cited by applicant]
Lewis, et al., “A common human beta globin splicing mutation modeled in mice”, Blood, 91:2152-6 (1998). [cited by applicant]
Konstan, et al., “Compacted DNA Nanoparticles Administered to the Nasal Mucosa of Cystic Fibrosis Subjects Are Safe and Demonstrate Partial to Complete Cystic Fibrosis Transmembrane Regulator Reconstitution”, Human Gene… [cited by applicant]
Kim, et al. “Insertion and deletion mutants of Fokl restriction endonuclease”, J. Biol. Chem. 269:31978-82 (1994b). [cited by applicant]
Kim, et al., “Chimeric restriction endonuclease”, PNAS, 91:883-7 (1994a). [cited by applicant]
Kim, et al., “USP17- and SCFβTrCP-Regulated Degradation of DEC1 Controls the DNA Damage Response”, Mol Cell Biol., 34(22):4177-85 (2014). [cited by applicant]
Karen, et al., “Angiokeratoma corporis diffusum (Fabry disease)”, Dermatol. Online J., 11(4): 8 (2005). [cited by applicant]
Kamei, et al., “Mechanistic study of the uptake/permeation of cell-penetrating peptides across a caco-2 monolayer and their stimulatory effect on epithelial insulin transport”, J Pharm Sci., 102(11):3998-4008 (2013). [cited by applicant]
Jia, et al., “Bacterial delivery of TALEN proteins for human genome editing”, PlosOne, 9(3):e91547 1-9 (2014). [cited by applicant]
Hubbell, et al., “Chemistry. Nanomaterials for drug delivery”, Science, 337:303-5 (2012). [cited by applicant]
Hutt, et al., “Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis”, Nat Chem Biol., 6:25-33 (2010). [cited by applicant]
Hu, et al., “ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays”, J Immunol Methods, 347:70-8 (2009). [cited by applicant]
Huang, et al., “Preparation and determination of optical purity of y-lysine modified peptide nucleic acid analogues”, Arch Pharm Res, 35(3):517-522 (2012). [cited by applicant]
Hrkach, et al., “Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile”, Sci Transl Med., 4:128ra139 (2012). [cited by applicant]
Hanna, et al., “Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin”, Science, 318:1920-3 (2007). [cited by applicant]
Holt, et al., “Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo”, Nature biotechnology, 28(8):839-47 (2010). [cited by applicant]
Haendel, et al., “Zinc-finger nuclease based genome surgery: it's all about specificity”, Gene Ther., 11:28-37 (2011). [cited by applicant]
Griesenbach, et al., “Gene transfer to the lung: Lessons learned from more than 2 decades ofCF gene therapy”, Advanced Drug Delivery Reviews, 61:128-139 (2009). [cited by applicant]
Green, “A combinatorial polymer library approach yields insight into nonviral gene delivery”, Acc Chem Res., 41(6):749-59 (2008). [cited by applicant]
Grafmueller, et al., “Bidirectional transfer study of polystyrene nanoparticles across the placental barrier in an ex vivo human placental perfusion model”, Enviro Health Perspectives, 123(12):1280-6 (2015). [cited by applicant]
Granio, et al., “Adenovirus 5-fiber 35 chimeric vector mediates efficient apical correction of the cystic fibrosis transmembrane conductance regulator defect in cystic fibrosis primary airway epithelia”, Human Gene Ther… [cited by applicant]